Tempus AI, Inc. reported significant financial growth in its latest quarterly results, with total net revenue reaching $314.6 million for the three months ended June 30, 2025, compared to $166.0 million for the same period in 2024, marking an increase of 90%. For the first half of 2025, revenue totaled $570.4 million, up from $311.8 million in the prior year, driven primarily by a substantial rise in genomic testing and data services. The company's genomics segment alone generated $241.8 million in the second quarter, a 115% increase year-over-year, largely attributed to the acquisition of Ambry Genetics, which expanded its hereditary testing capabilities.
Despite the revenue growth, Tempus reported a net loss of $42.8 million for the second quarter of 2025, a significant reduction from a loss of $552.2 million in the same quarter of 2024. The company’s losses for the first half of 2025 were $110.9 million, down from $617.0 million in the previous year. This improvement in net loss was influenced by a decrease in stock-based compensation expenses, which fell sharply due to the performance-based vesting conditions being satisfied in the prior year. Total operating expenses for the second quarter were $376.4 million, down from $699.5 million in the same period last year.
Strategically, Tempus has made notable advancements, including the acquisition of Ambry Genetics for $375 million in cash and stock, which is expected to enhance its testing capabilities in hereditary cancer risk. Additionally, the company acquired Deep 6 AI, which specializes in matching patients to clinical trials, for $17.4 million. These acquisitions are part of Tempus's broader strategy to leverage artificial intelligence in healthcare and expand its product offerings across various disease areas.
Operationally, Tempus has seen a significant increase in customer engagement, with the volume of genomic tests performed rising from approximately 66,500 in Q2 2024 to about 212,000 in Q2 2025. The company has also expanded its partnerships, working with over 200 biotech firms and 19 of the 20 largest public pharmaceutical companies. As of June 30, 2025, Tempus had cash and cash equivalents of $186.3 million, down from $341.8 million at the end of 2024, reflecting its investments in acquisitions and operational growth.
Looking ahead, Tempus anticipates continued revenue growth driven by its expanded product lines and strategic partnerships. The company expects to maintain high levels of investment in research and development, particularly in technology and product innovation, to support its long-term growth objectives. The management remains optimistic about achieving profitability as the demand for its genomic and data services continues to rise, supported by favorable reimbursement trends and an expanding customer base.
About Tempus AI, Inc.
Tempus AI is a healthcare technology company specializing in precision medicine through Intelligent Diagnostics. It combines AI, genomic, clinical, and imaging data to develop personalized, accurate laboratory tests across oncology, neuropsychiatry, cardiology, and infectious diseases. Its platform integrates vast multimodal datasets, enabling data-driven therapy decisions, clinical trial matching, and drug discovery, serving healthcare providers, researchers, and life sciences companies worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.